Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021
Abstract Objective: To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity. Design: Prospective cohort study...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-01-01
|
| Series: | Antimicrobial Stewardship & Healthcare Epidemiology |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2732494X22003758/type/journal_article |
| _version_ | 1797755118716715008 |
|---|---|
| author | Rachel E. Bosserman Christopher W. Farnsworth Caroline A. O’Neil Candice Cass Daniel Park Claire Ballman Meghan A. Wallace Emily Struttmann Henry Stewart Olivia Arter Kate Peacock Victoria J. Fraser Philip J. Budge Margaret A. Olsen Carey-Ann D. Burnham Hilary M. Babcock Jennie H. Kwon for the CDC Prevention Epicenters |
| author_facet | Rachel E. Bosserman Christopher W. Farnsworth Caroline A. O’Neil Candice Cass Daniel Park Claire Ballman Meghan A. Wallace Emily Struttmann Henry Stewart Olivia Arter Kate Peacock Victoria J. Fraser Philip J. Budge Margaret A. Olsen Carey-Ann D. Burnham Hilary M. Babcock Jennie H. Kwon for the CDC Prevention Epicenters |
| author_sort | Rachel E. Bosserman |
| collection | DOAJ |
| description |
Abstract
Objective:
To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity.
Design:
Prospective cohort study.
Setting:
An academic, tertiary-care hospital in St. Louis, Missouri.
Participants:
The study included 400 HCP aged ≥18 years who potentially worked with coronavirus disease 2019 (COVID-19) patients and had no known history of COVID-19; 309 of these HCP also completed a follow-up visit 70–160 days after enrollment. Enrollment visits took place between September and December 2020. Follow-up visits took place between December 2020 and April 2021.
Methods:
At each study visit, participants underwent SARS-CoV-2 IgG N-antibody testing using the Abbott SARS-CoV-2 IgG assay and completed a survey providing information about demographics, job characteristics, comorbidities, symptoms, and potential SARS-CoV-2 exposures.
Results:
Participants were predominately women (64%) and white (79%), with median age of 34.5 years (interquartile range [IQR], 30–45). Among the 400 HCP, 18 (4.5%) were seropositive for IgG N-antibodies at enrollment. Also, 34 (11.0%) of 309 were seropositive at follow-up. HCP who reported having a household contact with COVID-19 had greater likelihood of seropositivity at both enrollment and at follow-up.
Conclusions:
In this cohort of HCP during the first wave of the COVID-19 pandemic, ∼1 in 20 had serological evidence of prior, undocumented SARS-CoV-2 infection at enrollment. Having a household contact with COVID-19 was associated with seropositivity.
|
| first_indexed | 2024-03-12T17:42:15Z |
| format | Article |
| id | doaj.art-002815063179414c9efb6253f98afc47 |
| institution | Directory Open Access Journal |
| issn | 2732-494X |
| language | English |
| last_indexed | 2024-03-12T17:42:15Z |
| publishDate | 2023-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Antimicrobial Stewardship & Healthcare Epidemiology |
| spelling | doaj.art-002815063179414c9efb6253f98afc472023-08-04T01:46:13ZengCambridge University PressAntimicrobial Stewardship & Healthcare Epidemiology2732-494X2023-01-01310.1017/ash.2022.375Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021Rachel E. Bosserman0https://orcid.org/0000-0002-4844-4212Christopher W. Farnsworth1Caroline A. O’Neil2https://orcid.org/0000-0003-2966-0750Candice Cass3Daniel Park4Claire Ballman5Meghan A. Wallace6Emily Struttmann7Henry Stewart8https://orcid.org/0000-0003-0767-5361Olivia Arter9Kate Peacock10Victoria J. Fraser11Philip J. Budge12https://orcid.org/0000-0002-0069-2372Margaret A. Olsen13https://orcid.org/0000-0001-7070-9320Carey-Ann D. Burnham14Hilary M. Babcock15https://orcid.org/0000-0001-9015-8378Jennie H. Kwon16for the CDC Prevention EpicentersDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MissouriDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MissouriDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri Abstract Objective: To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity. Design: Prospective cohort study. Setting: An academic, tertiary-care hospital in St. Louis, Missouri. Participants: The study included 400 HCP aged ≥18 years who potentially worked with coronavirus disease 2019 (COVID-19) patients and had no known history of COVID-19; 309 of these HCP also completed a follow-up visit 70–160 days after enrollment. Enrollment visits took place between September and December 2020. Follow-up visits took place between December 2020 and April 2021. Methods: At each study visit, participants underwent SARS-CoV-2 IgG N-antibody testing using the Abbott SARS-CoV-2 IgG assay and completed a survey providing information about demographics, job characteristics, comorbidities, symptoms, and potential SARS-CoV-2 exposures. Results: Participants were predominately women (64%) and white (79%), with median age of 34.5 years (interquartile range [IQR], 30–45). Among the 400 HCP, 18 (4.5%) were seropositive for IgG N-antibodies at enrollment. Also, 34 (11.0%) of 309 were seropositive at follow-up. HCP who reported having a household contact with COVID-19 had greater likelihood of seropositivity at both enrollment and at follow-up. Conclusions: In this cohort of HCP during the first wave of the COVID-19 pandemic, ∼1 in 20 had serological evidence of prior, undocumented SARS-CoV-2 infection at enrollment. Having a household contact with COVID-19 was associated with seropositivity. https://www.cambridge.org/core/product/identifier/S2732494X22003758/type/journal_article |
| spellingShingle | Rachel E. Bosserman Christopher W. Farnsworth Caroline A. O’Neil Candice Cass Daniel Park Claire Ballman Meghan A. Wallace Emily Struttmann Henry Stewart Olivia Arter Kate Peacock Victoria J. Fraser Philip J. Budge Margaret A. Olsen Carey-Ann D. Burnham Hilary M. Babcock Jennie H. Kwon for the CDC Prevention Epicenters Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 Antimicrobial Stewardship & Healthcare Epidemiology |
| title | Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 |
| title_full | Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 |
| title_fullStr | Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 |
| title_full_unstemmed | Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 |
| title_short | Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021 |
| title_sort | seroprevalence of severe acute respiratory coronavirus virus 2 sars cov 2 antibodies among healthcare personnel in the midwestern united states september 2020 april 2021 |
| url | https://www.cambridge.org/core/product/identifier/S2732494X22003758/type/journal_article |
| work_keys_str_mv | AT rachelebosserman seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT christopherwfarnsworth seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT carolineaoneil seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT candicecass seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT danielpark seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT claireballman seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT meghanawallace seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT emilystruttmann seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT henrystewart seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT oliviaarter seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT katepeacock seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT victoriajfraser seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT philipjbudge seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT margaretaolsen seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT careyanndburnham seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT hilarymbabcock seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT jenniehkwon seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 AT forthecdcpreventionepicenters seroprevalenceofsevereacuterespiratorycoronavirusvirus2sarscov2antibodiesamonghealthcarepersonnelinthemidwesternunitedstatesseptember2020april2021 |